Cyclophosphamide

"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Descriptor ID	D003520
MeSH Number(s)	D02.455.526.728.650.730.243 D02.705.672.500.243
Concept/Terms	Cyclophosphamide Cyclophosphamide Cytophosphane Cyclophosphamide Monohydrate Monohydrate, Cyclophosphamide Cyclophosphane Cyclophosphamide Anhydrous Cyclophosphamide Anhydrous Anhydrous, Cyclophosphamide Cyclophosphamide, (R)-Isomer Cyclophosphamide, (R)-Isomer Cyclophosphamide, (S)-Isomer Cyclophosphamide, (S)-Isomer Cytophosphan Cytophosphan Endoxan Endoxan Neosar Neosar NSC-26271 NSC-26271 NSC 26271 NSC26271 Procytox Procytox Sendoxan Sendoxan B-518 B-518 B 518 B518 Cytoxan Cytoxan

Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Phosphoramide Mustards [D02.455.526.728.650.730]
Cyclophosphamide [D02.455.526.728.650.730.243]
Organophosphorus Compounds [D02.705]
Phosphoramides [D02.705.672]
Phosphoramide Mustards [D02.705.672.500]
Cyclophosphamide [D02.705.672.500.243]

Below are MeSH descriptors whose meaning is related to "Cyclophosphamide".

Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".

Cyclophosphamide
Ifosfamide

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.

Bar chart showing 43 publications over 22 distinct years, with a maximum of 5 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1998	0	1	1
2002	1	1	2
2003	0	3	3
2004	2	0	2
2005	1	0	1
2006	0	3	3
2007	1	1	2
2008	1	2	3
2009	1	1	2
2010	1	1	2
2011	1	0	1
2012	0	2	2
2013	1	3	4
2014	2	3	5
2015	0	1	1
2017	1	1	2
2019	1	1	2
2020	0	1	1
2021	0	1	1
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.

Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034.

View in: PubMed
Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, Clement AM, Nielsen JS, Quizi J, Yung E, Brown SD, Dreolini L, Waller DD, Smazynski J, Gierc NS, Loveless BC, Clark K, Dyer T, Hogg R, McCormick L, Gignac M, Bell S, Chapman DM, Bond D, Yong S, Fung R, Lockyer HM, Hodgson V, Murphy C, Subramanian A, Wiebe E, Yoganathan P, Medynski L, Vaillan DC, Black A, McDiarmid S, Kennah M, Hamelin L, Song K, Narayanan S, Rodrigo JA, Dupont S, Hawrysh T, Presseau J, Thavorn K, Lalu MM, Fergusson DA, Bell JC, Atkins H, Nelson BH, Holt RA. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front Immunol. 2022; 13:1074740.

View in: PubMed
Gonz?lez-Mel?ndez A, Medina-Parrilla EJ, V?lez R, Vil? LM. Isolated intestinal polyarteritis nodosa in an elderly patient. BMJ Case Rep. 2021 Mar 04; 14(3).

View in: PubMed
Chambers LM, Kuznicki M, Yao M, Chichura A, Gruner M, Reizes O, Debernardo R, Rose PG, Michener C, Vargas R. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020 12; 159(3):699-705.

View in: PubMed
Bagnall-Moreau C, Chaudhry S, Salas-Ramirez K, Ahles T, Hubbard K. Chemotherapy-Induced Cognitive Impairment Is Associated with Increased Inflammation and Oxidative Damage in the Hippocampus. Mol Neurobiol. 2019 Oct; 56(10):7159-7172.

View in: PubMed
Avila-Ornelas J, Labat E, Alfonso G, Serrano C, Fiorito F. An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report. Mult Scler Relat Disord. 2019 Jun; 31:51-53.

View in: PubMed
Gago R, Shum LM, Vil? LM. Right upper quadrant abdominal pain as the initial presentation of polyarteritis nodosa. BMJ Case Rep. 2017 Feb 22; 2017.

View in: PubMed
Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017 01; 116(3):324-334.

View in: PubMed
Salas-Ramirez KY, Bagnall C, Frias L, Abdali SA, Ahles TA, Hubbard K. Doxorubicin and cyclophosphamide induce cognitive dysfunction and activate the ERK and AKT signaling pathways. Behav Brain Res. 2015 Oct 01; 292:133-41.

View in: PubMed
Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Porter-Scott M, Smith JJ, Moyer MP, Copeland RA, Pollock RM, Kuntz KW, Raimondi A, Keilhack H. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS One. 2014; 9(12):e111840.

View in: PubMed

People

Explore

Similar Concepts

Top Journals